Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week”In the company’s words, NCT03305016 on ClinicalTrials.gov
- Tested for
- Growth Hormone Deficiency, Pediatric (2 trials), Endocrine System Diseases (2 trials), Hormone Deficiency (2 trials), Pituitary Diseases (2 trials), Adult Growth Hormone Deficiency, Growth Hormone Deficiency (GHD)
- Main trialPhase 3
- “A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.”In the company’s words, NCT03305016 on ClinicalTrials.gov
- Other names
- TransCon hGH
- Given with
- Omnitrope (Sandoz)Other companies’ drugs in its trials
Other drugs for Growth Hormone Deficiency, Pediatric
- LUM-201Lumos Pharma · Phase 3
- GB06Kexing Biopharm Co., Ltd. · Phase 3
- InpegsomatropinXiamen Amoytop Biotech Co., Ltd. · Phase 2
- GenSci134Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
- Recombinant Human Growth HormoneChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 19 Mar 2019 | A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency | |
| Phase 3Completed | 21 Feb 2023 | A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial | |
| Phase 2Completed | May 2011 | A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency | |
| Phase 2Completed | Jul 2015 | Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026